The authors extended this analysis to breast (E0771) and skin (B16-F10) syngeneic tumor models, which are poorly responsive to immune checkpoint inhibitors (ICI), and demonstrated that IL-27 was not effective as single treatment but synergized with ICI to control or delay tumor progression. The gene discussed is IL27; the disease is neoplasm.